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Abstract. The effect of calcium channel blockers on the
progression of renal failure is controversial. In contrast
with earlier studies, we recently reported that modera-
tely large doses of verapamil significantly accelerated
chronic renal failure in the rat remnant kidney model
[1]. Studies reporting beneficial effects of verapamil
were characterised by a much lower dose of verapamil
and by the start of treatment immediately after renal
ablation, which potentially interfered with the initial
phase of remnant kidney hypertrophy. We therefore
studied the effects of a high, fully antihypertensive oral
dose of verapamil (100-150 mg/kg/per day; group Vera
high) and a low, haemodynamically almost ineffective
dose (10-15 mg/kg per day; group Vera low), on the
progression of chronic renal failure in female Wistar rats
with 5/6 nephrectomy. The treatment was started no
earlier than 5 weeks after renal ablation, and matched
groups of 20 animals were followed for 16 weeks
thereafter. High-dose verapamil reduced systolic blood
pressure to median values of 130-140 mmHg through-
out the experimental period, whereas blood pressure in
Vera low animals remained elevated at median values of
165-172 mmHg similar to non-treated rats with 172-185
mmHg median systolic blood pressure.
Despite control of hypertension, proteinuria
increased more rapidly and to more elevated values in
the Vera high animals (5.98 ± 0.91 mg/jumol creatinine
before death/sacrifice) than in the Vera low and control
groups (3.08 ± 0.91 and 3.60 ± 0.71 mg//imol creati-
nine, respectively, P < 0.05 vs Vera high), and signifi-
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cantly more animals died during the observation period
in the Vera high compared to the control group (6 of 20
vs lof 20, P < 0.05). Kidney remnants were larger in the
Vera high group, mainly due to tubulointerstitial
changes with filling of dilated tubular lumina with
proteinaceous casts. Mean glomerular diameter did not
differ between groups, and the percentage of glomeruli
with segmental or global glomerulosclerosis was not
significantly increased in the Vera high group.
It is concluded that chronic high-dose verapamil
therapy in the 5/6 nephrectomy model, albeit effective
in controlling hypertension, is deleterious to renal
function when remnant hypertrophy has previously
been allowed to occur. A low, haemodynamically
barely effective, dose of verapamil fails to alter the
course of renal failure in this setting.
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Introduction
Antihypertensive therapy has been shown to retard
progressive chronic renal failure in various rat models of
experimental renal disease [1-6] and also in humans
with diabetic nephropathy [7,8] as well as other primary
renal diseases [9-11]. However, in the most extensively
studied model of chronic renal failure, the remnant-
kidney rat, the response to different antihypertensive
regimens is not uniform. Control of hypertension by
Verapamil and Rat Remnant Kidney
ACE inhibitors has proven to be superior to triple-drug
therapy with hydralazine, reserpine, and hydrochloro-
thiazide regarding prevention or delay in progressive
glomerulosclerosis [12], and the highly protective effect
of ACE inhibitors was invariably associated with greatly
reduced proteinuria [1, 12, 13].
In contrast to the clear-cut beneficial effects of ACE
inhibitors, studies with calcium channel blocking agents
have yielded conflicting results. Harris et al [14] injected
a small dose of twice 0.1 mg/kg verapamil daily.
Although lacking any antiproteinuric or antihyper-
tensive action, this small dose of verapamil prolonged
survival when applied to male Wistar rats starting 1
week after renal ablation. Eliahou et al [15] adminis-
tered nisoldipine starting immediately after renal
ablation, which prevented hypertension, had little effect
on proteinuria, but improved survival in male and
female Charles River rats. These reports of beneficial
effects of calcium antagonists are at variance with
studies in remnant-kidney rats performed earlier in our
laboratory [1] and by Jackson et al [13]. The latter
authors reported a tendency to increased proteinuria in
female Sprague-Dawley rats despite excellent control
of hypertension after 6 weeks of treatment with the
calcium channel blocker felodipine.
In our previous study [1], verapamil at a concentra-
tion of 0.5-0.7 g/1 in the drinking water starting 5 weeks
after renal ablation was found to increase proteinuria,
to promote glomerulosclerosis and to shorten survival in
female Wistar rats. However, the amount of verapamil
consumed from the drinking water failed to reduce the
elevated blood pressure reliably because it fell short of
100 mg/kg per day in many animals. The present study
was therefore undertaken to compare the outcome in
remnant-kidney rats receiving a fully antihypertensive
dose of 100-150 mg/kg oral verapamil daily [16] to
another group receiving the relatively low dose of 10-15
mg/kg per day of oral verapamil.
Methods
Renal ablation was performed in a total of 100 female
Wistar rats over a 4 week period. Once weekly a group
of 25 animals weighing 110-130 g was subjected to
partial infarction of the left kidney as previously des-
cribed [1]. In short, 2-3 upper branches of the left renal
artery were tied off, followed by right nephrectomy 1
week later. Another 5 weeks later, the rats were placed
in individual metabolic cages for 2 days. The 24-h urine
of the second day was used to determine proteinuria and
creatinine excretion. Blood was obtained from the cut
end of the tail. Arterial blood pressure was measured
by tail plethysmography in the awake animals. Since
the range of the plethysmograph used did not exceed
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200 mmHg, pressures over 200 were recorded as
'205' mmHg for non-parametric statistical evaluation. Of
each group of 25 rats, five triplets with similar degree of
proteinuria and hypertension were selected, while the
remaining ten rats were excluded from further study.
One rat of each triplet was then allocated at random to
one of the two experimental groups and the control
group. We thus obtained four subgroups of five animals
in each of the experimental and the control groups.
These subgroups were housed in group cages with tap
water ad lib. The animals were offered 14 g/rat per day
of a standard ground rat diet (Klingentalmuhle AG,
Basel) containing 30% protein (casein IA) and 20 mmol
NaCl per kg food. Left-over food was weighed. Com-
mencing 5 weeks and a few days after nephrectomy, one
group of 20 rats (Vera high) received verapamil in
concentrations of 1.43 g/kg food and 250 mg/1 drinking
water. This was intended to result in an oral verapamil
intake of 100-150 mg/kg rat (each animal receiving 20
mg in the daily food allowance of 14 g and 5-10 mg with
the drinking water). The second group (Vera low)
received one-tenth of this dose (0.143 g/kg food and 25
mg/1 drinking water). Every 4 weeks, the animals were
placed into the metabolic cages for 2 days to determine
proteinuria and creatinine clearance followed by
plethysmographic measurement of blood pressure in the
afternoon of the third day.
Treatment was carried on for a total of 16 weeks
unless the animals had to be killed earlier because they
developed uraemic symptoms such as decreased food
intake, weight loss and listlessness, and looked sick and
miserable. At the end of the experimental period, mean
arterial blood pressure and heart rate were measured:
the animals received inactin 50-90 mg/kg i.p. and were
placed on a heated animal board to keep rectal tempera-
ture between 37 and 38°C. A polyethylene cannula was
then placed in the left carotid artery and connected to a
Statham transducer with a Hellige recorder. After
obtaining stable readings for heart rate and blood
pressure for at least 10 min, the animals were exsanguin-
ated for determination of blood chemistry and the heart
and kidney were removed and weighed.
A Beckman creatinine analyser was used to measure
creatinine in plasma and urine, and the central hospital
laboratories' multichannel Hitachi analyser for deter-
mining creatinine, urea, electrolytes, and lipids at sacri-
fice. Plasma albumin was measured colorimetrically
with bromcresol green [17]. Urinary protein content
was determined by tannic acid precipitation with Fe3+
colorimetry as described by Yatzidis [18]. Proteinuria
was expressed as mg protein excreted per fimol creati-
nine. For histological examination, the kidneys were
fixed in phosphate-buffered 4% formalin. Three /zm
sections were stained with H & E, PAS, periodic acid/
silver methenamine, and chromotrope aniline-blue.
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One hundred glomeruli were examined in each kidney
for the presence or absence of segmental or global
glomerular sclerosis. Care was taken to evaluate renal
histology in intact parts of the remnant kidneys outside
of scarred regions close to infarcted areas. Mean glo-
merular diameter for each kidney was calculated from
15 to 40 individual non-sclerosed glomerular cross-
sectional areas using the graphic tablet cursor (Kontron
Miinchen). The pathologist (M. J. Mihatsch) evaluated
renal histology without knowledge of the treatment the
rats had received.
Results are expressed either as means ± SEM, or as
medians and range. Mann-Whitney's U-test, Fisher's
exact test, and the Spearman rank correlation were used
for statistical evaluation as appropriate.
Results
As described previously [1], our technique of tying off
2-3 upper branches of the left renal artery combined
with contralateral nephrectomy resulted in an at least
4/5 reduction of renal mass. No drugs were given for
5 weeks after nephrectomy to allow undisturbed
hypertrophy of the kidney remnants and growth of the
animals. They had thus reached body weights of 170-
200 g when the control and the two experimental groups
were formed. Animals with similar degrees of hyper-
tension and proteinuria were allocated to the three
groups, as reflected by the homogeneous baseline
values for creatinine clearance, proteinuria, and systolic
blood pressure (Tables 1 and 2).
Table 1. Renal function and proteinuria before commencing verapa-
mil
Control Vera low Vera high
(n = 20) (n = 20) (n = 20)
20
n surviving
Pcr0*mol/1) 71 ±3
CCr (^ 1/min per 100 g body-wt) 282±9
Proteinuria (mg/|imol Cr) 1.41 ±0.23
69±3 73±3
279+11 281 ±14
1.45±0.26 1.43±0.23
All values are mean±SEM.
In the control group a single animal developed urae-
mic symptoms towards the end of the experimental
period and had to be sacrificed (Fig. 1). In the Vera low
group, one rat died spontaneously on day 9 and a second
animal had to be sacrificed on day 54. In the Vera high
group, six animals died before 16 weeks: two died
spontaneously (at 61 days and at 105 days after starting
high-dose verapamil treatment), the other four were
sacrificed between days 53 and 87 because of uraemic
symptoms such as listlessness, failure to eat, and weight
loss. Their blood urea concentrations were between 63
15-
J- r
2 0
era low - * - Vera til«h
0 20 40 60 80 100
days on treatment
Fig. 1. Survival curve showing greater mortality in Vera high group
(14 of 20 rats surviving; P < 0.05 v control with 19 of 20 rats surviving).
and 112 mmol/1. Mortality in the Vera high group (6 of
20 rats) was significantly greater than in the control
group (1 of 20 rats, P < 0.05, Fisher's exact test).
The surviving animals continued to grow during the
treatment period. In the control group body weight
increased from 192 ± 3 g (n = 20) to 244 ±5 g (n= 19),
in the Vera low group from 179 ± 3 (n = 20, P < 0.05 vs
control) to 228 ± 5 g (n = 18, n.s. vs control) and in the
Vera high group from 184 ± 3 g (n = 20, n.s. vs control
and Vera low) to 221 ± 5 g (n - 14, P < 0.05 vs control,
n.s. vs Vera low).
Blood Pressure
The majority of the rats were hypertensive at the time of
forming the experimental and the control groups (Table
2). High-dose verapamil (Vera high group) reduced
systolic blood pressure to values well below baseline and
the decrease in blood pressure persisted throughout the
experimental period. The average consumption of vera-
pamil in this group amounted to approximately 25 mg or
130 mg/kg daily at the beginning and decreased slightly
to about 110 mg/kg at the end of the experimental
period as the animals gained some weight.
No effect on awake systolic blood pressure was
observed in the Vera low group which received 10 to 15
mg/kg per day of oral verapamil. In both the control and
the Vera low groups, systolic blood pressure remained
essentially unchanged throughout the observation
period (Table 2).
Proteinuria and Renal Function
Mean values for baseline renal function and proteinuria
are shown in Table 1. Creatinine clearance in surviving
animals was about 50% of normal throughout the
observation period and did not differ among groups. At
16 weeks, mean values were 306 ± 20 jiil/min per 100 g
Verapamil and Rat Remnant Kidney
Table 2. Systolic blood pressure and proteinuria at 4 week intervals during verapamil treatment
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Before treatment
(n=20/20/20)
Week 4
(n=20/19/20)
Week 8
(n=20/19/19)
Week 12
(n=20/18/17)
Week 16
(n=19/18/14)
Median
(range)
Median
(range)
Median
(range)
Median
(range)
Median
(range)
Systolic blood
Control
172
(125->200)
175
(130->200)
175
(130->200)
175
(125->200)
185
(125->200)
pressure (mmHg)
Vera low
170
(125->200)
165
(130->200)
170
(130->200)
172
(130->200)
162
(135->200)
Vera high
165
(130->200)
140°oo/**»
(125-160)
130°°°'"*
(120-160)
135<xx>/tt*
(115-180)
140ooo/***
(115-150)
Proteinuria
Control
1.18
(0.23-4.53)
0.93
(0.14-4.48)
1.23
(0.15-7.34)
1.76
(0.20-8.28)
1.56
(0.31-10.7)
(mg/fimol Cr)
Vera low
1.18
(0.22-5.45)
1.56
(0.27-12.9)
1.80
(0.21-14.7)
1.73
(0.27-10.9)
2.34
(0.25-5.24)
Vera high
1.20
(0.36-4.00)
1.53
(0.38-11.4)
2.96*
(0.33-10.9)
3.46
(0.49-14.8)
3.32
(0.86-11.0)
P (Mann-Whitney U-test) vs control * < 0.05 *** < 0.001, Vera high vs Vera low °°° < 0.001
rat (n = 19) for the control, 295 ± 27 jul/min per 100 g rat
(n = 18) for the Vera low, and 305 ± 2 jul/min per 100 g
rat (n = 14) for the Vera high group. Those rats that
died or had to be sacrificed earlier, had rapidly increas-
ing plasma creatinine to final concentrations between
144 and 295 jonol/1.
As noted in previous studies, the range of proteinuria
was extremely wide, but baseline values in the two
experimental groups and the control group (Fig. 2) did
not differ significantly. The extremes of 0.2 and 10 mg/
j«nol creatinine correspond to daily protein excretion
rates of 6 and 300 mg per 100 g body-weight.
Proteinuria increased in the majority of the animals
(Fig. 2). However, there were distinct differences
between groups. The median level of proteinuria
increased only minimally in the control group, whereas
it doubled in the Vera low group and reached three
20
 n
1 5 -
mg/umol Cr
20 -i
mg/ymol Cr
20 -i
mg/umol Cr
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weeks
Control
12 16 0 4 8
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12
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16 0 4 8
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Fig. 2. Proteinuria of individual animals at 0, 4, 8, 12, and 16 weeks
after starting treatment with verapamil. + denotes non-surviving rat.
Proteinuria is shown to increase more rapidly in Vera high group
compared to both Vera low group and control.
times the initial value in the Vera high group (Table 2).
This enhancement of proteinuria by high-dose verapa-
mil was all the more striking as the six rats with the most
rapidly increasing protein excretion rates of this group
did not survive to the end of the 16 weeks' experimental
period. Average proteinuria before death or sacrifice
for all 20 rats in each group was significantly greater in
group Vera high with 5.98 ± 0.91 mg/^mol creatinine
compared to Vera low with 3.08 ± 0.70 mg//imol
creatinine (P < 0.02) and to the control group with 3.60
± 0.71 mg/umol creatinine (P < 0.05). The average
slope of the increase in proteinuria was significantly
greater in the Vera high than in both the Vera low group
and the control group (P < 0.01 by ANOVA).
Other Observations
Heart rate and mean arterial blood pressure measured
in the survivors after 16 weeks of observation are shown
in Table 3. Both were markedly lower in the Vera high
group, whereas no statistically significant differences
were found between the Vera low and the control
group. Wet heart weights did not differ between groups
despite excellent control of hypertension in the Vera
high group.
Plasma albumin concentration at death or sacrifice
was 33.8 ± 0.7 g/1 (n = 20) in the control group and 30.4
± 0.9 g/1 {n = 18) in the Vera high group (P < 0.01).
Plasma albumin in the Vera low rats (32.2 ± 0.6 g/1, n =
19) did not differ significantly from either the control or
the Vera high group. Plasma cholesterol levels at death
or sacrifice varied greatly among individul animals. The
mean level was significantly lower in the Vera low group
(2.05 ± 0.23 /zmol/1, n = 19) than in the Vera high group
(2.79 ± 0.25 jumol/1, n = 18, P < 0.01). The mean level
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Table 3. Mean arterial blood pressure, heart rate, heart weight, and
body-weight after 16 weeks of verapamil
Control Vera low Vera high
(n = 19) (n = 18) (« = 14)
Mean arterial BP (mmHg)
Heart rate
Heart wet weight
(g/100 g body-wt)
Body weight (g)
180±8
422 ±6
0.32±0.01
244±5
156±7
393 ±14
0.34±0.01
228±5
124±3*.*.*
358±6*.*.*
0.35±0.01
221±5*
All values are mean±SEM.
P (Mann-Whitney U-test) vs control * < 0.05 *** < 0.001
Vera high vs Vera low °° < 0.01
of the control group was intermediate (2.44 ± 0.24
jumol/1, n = 20) and did not differ significantly from
either of the two verapamil groups.
Kidney Weight and Histology
The wet weights of the kidney remnants obtained
immediately after sacrifice did not differ between the
control and the Vera low group (Table 4). In the Vera
high group, however, the kidney remnants were gener-
ally larger and most of them weighed more than the
medians of the two other groups. The difference in
kidney size was mainly due to tubulointerstitial changes,
with markedly dilated tubular structures filled by pro-
teinaceous cast material (Fig. 3). The mean diameter of
non-sclerosed glomeruli did not differ between groups
and within-group correlations between mean glomeru-
lar diameter and kidney weight were not significant.
The percentage of glomeruli with segmentally or
totally sclerosed capillary tufts ranged between 0% and
some 90% in each of the three groups (Table 4). The
median percentage of sclerosed glomeruli was 14% in
the Vera high group, 11% in the Vera low, and 7% in
the control rats (n.s.). Those rats that did not survive up
to the end of the 16 weeks had between 66% and 92%
segmentally or totally sclerosed glomeruli. As shown in
Fig. 4, increasing kidney weights were associated with
Fig. 3. Whole kidney sections (left) of rat No. 39, control group
(systolic blood pressure consistently above 200 mmHg, proteinuria
increasing from 0.6 to 1.6 mg/^mol Cr at 16 weeks), and (right) of rat
No. 43, Vera high group (systolic blood pressure lowered from above
200 mmHg to 140-155 mmHg at 4-12 weeks, proteinuria increasing
from 1.6 to 11.0 mg/^mol Cr, sacrificed at 13 weeks of treatment).
Note enlargement due to dilated tubular structures with darkly
staining proteinaceous casts in verapamil kidney (x 2.7; chromotope
aniline-blue stain).
% sclerosed glomeruli
8 0 -
4 0 -
2 0 -
0.25 1.250.75 1
Kidney weight g/100g BW
Fig. 4. Proportion of sclerosed glomeruli in relation to kidney wet
weight. Animals dying before the end of the 16 weeks experimental
period are marked with O. The percentage of sclerosed glomeruli and
kidney weight are significantly correlated in all three groups (control
group Spearman r = 0.766, P < 0.002; group Vera low r = 0.819, P <
0.002; group Vera high r = 0.814, P < 0.002).
Table 4. Remnant kidney weight and histology
Control
(n = 20)
Vera low
(« = 19)
Vera high
(n = 18)
Kidney wet weight
(g/100 g body weight)
Glomerulosclerosis
(% sclerosed glom.)
Mean glomerular
diameter (nm)
Median
(range)
Median
(range)
Mean±SEM
0.49
(0.34-0.83)
7
(0-89)
137±2
0.48
(0.38-1.09)
11
(0-84)
132±3
0.58"=
(0.46-1.44)
14
(1-92)
135±2
P (Mann-Whitney U-test) vs control ** < 0.01
Vera high vs Vera low ° < 0.05
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increasing proportions of sclerosed glomeruli (Spear-
man r = 0.814 (Vera high), r = 0.819 (Vera low), r =
0.766 (control), P < 0.002 in each group). However, for
any degree of glomerulosclerosis, the kidneys generally
appeared to be larger in the Vera high group.
The percentage of segmentally or totally sclerosed
glomeruli was highly significantly correlated in all
groups with final proteinuria (control group Spearman r
= 0.870, P < 0.002, Vera low r = 0.888, P < 0.002,
Vera high r = 0.915, P < 0.002) as well as with plasma
creatinine concentration at sacrifice (control group r =
0.558, P < 0.01, Vera low r = 0.892, P < 0.001, Vera
high r = 0.875, P < 0.001). Regarding blood pressure,
highly significant correlations were obtained between
systolic blood pressure in the awake rat before starting
treatment and the degree of glomerulosclerosis (control
group r = 0.720, P < 0.001, Vera low r = 0.728, P <
0.001, Vera high r = 0.603, P < 0.005). Similarly, at
least for groups Vera low and control, glomerulosclero-
sis was also significantly correlated with final systolic
blood pressure (control group r = 0.703, P < 0.001,
Vera low r = 0.459, P < 0.05 for all survivors, r = 0.605,
P < 0.01 excluding the one uraemic survivor with a
plasma urea of 118 mmol/1). However, as a consequence
of the antihypertensive efficacy of high-dose verapamil,
final systolic blood pressure differed little among rats of
the Vera high group and was thus not correlated
significantly with glomerulosclerosis (r = 0.298, n.s.).
Discussion
The present study demonstrates that effective control of
hypertension with verapamil not only failed to protect
from progressive renal damage but shortened survival
and enhanced proteinuria in a rat remnant kidney
model. This confirms our previous observation with
relatively high though not reliably antihypertensive
dosage of verapamil, which aggravated proteiuria,
tended to worsen glomerulosclerosis, and shortened
survival in the same rat model [1]. As in this previous
study, the higher and now effectively antihypertensive
dosage of verapamil was again associated with signifi-
cantly larger remnant kidneys. The increase in kidney
size was also due to tubulointerstitial changes, with
massive dilatation of tubules which were filled by
proteinaceous casts. The size of the non-sclerosed glo-
meruli, however, was by no means greater than in
control remnants. Remnant kidney enlargement thus
appeared not to be due to hypertrophy of viable renal
tissue but was probably the consequence of the exagger-
ated proteinuric response to verapamil treatment with
filling of nephrons with proteinaceous cast material.
An adverse effect of calcium channel blockers on the
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rat remnant kidney has not been found by some other
investigators. Harris et al [14] reported improved survi-
val when administering as little as 0.2 mg/kg body-
weight s. c. in two divided doses in male Munich Wistar
rats with renal ablation performed according to almost
the same procedure as in the present study. This small
amount of verapamil, which is less than 2% of the dose
used in the Vera low group of the present study, failed
to have any demonstrable effect on systemic haemody-
namics, glomerular filtration rate, renal blood flow, and
proteinuria [14, 19]. Protection against progressive
chronic renal failure was thought to be due to a peculiar
combination of unchanged glomerular capillary hyper-
tension and increased proximal tubular pressure [19].
Histologically, this minute dose of verapamil had no
effect on tubular morphology studied at 4 weeks [19] but
appeared to prevent or delay uraemic nephrocalcinosis
[20]. The two salient differences in experimental design,
compared to the present study were the early start of
verapamil treatment, which may have affected the
period of remnant glomerular hypertrophy during the
first 5 weeks after renal ablation, and more importantly
the much smaller though parenterally applied dosage.
Unfortunately, precise information on the bioavail-
ability of oral verapamil in the rat is lacking. In humans,
some 80% of oral verapamil is removed by the first-pass
effect through the liver. Assuming a similar bioavail-
ability of 20% for verapamil in the rat, the dose applied
by Harris et al [14] would have been ten times smaller
than the dose given to the Vera low group and one
hundred times smaller than the dose needed to effecti-
vely control hypertension in the Vera high group of the
present study or in the spontaneously hypertensive rat
[16]. At first sight, this dosage may seem excessive
compared to the clinical dosage of verapamil needed to
control hypertension in humans. However, as shown by
Fleckenstein's group [16, 21], the orally effective anti-
hypertensive dosages of a broad selection of calcium
channel blocking agents - from nifedipine to diltiazem -
were found to be 30 to over 100 times greater for the
spontaneously hypertensive rat compared to the
human. Rather than being toxic, 100-150 mg per kg
verapamil prevented early mortality and prolonged life
span of spontaneously hypertensive rats by some 50%
[22].
Whilst Harris et al [14] thus administered their cal-
cium channel blocker in a haemodynamically ineffective
dose, Eliahou et al [15] used oral nisoldipine, another
calcium channel blocker, in a relatively small dose of
0.3-0.6 mg/kg per day that was effective initially in
preventing and later in attenuating hypertension in male
and female rats. In contrast to the present study where
initial remnant kidney hypertrophy was allowed to
occur undisturbed by drug interference, Eliahou et al
started nisoldipine immediately after renal ablation.
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This may suggest that calcium channel blockers exert a
protective effect only when started before remnant
nephron hypertrophy and the hypertensive state are
fully established. It is also intriguing to note that
nisoldipine and to a lesser extent hydralazine improved
survival though not affecting the heavy proteinuria. The
finding of protection against progressive chronic renal
failure without an antiproteinuric effect by Eliahou et al
[15] as well as by Harris et al [14] is unique. In all other
studies of protection afforded by antihypertensive drugs
[1, 2, 5,11,12], by dietary measures such as low-protein
diet [23, 24], low-phosphorus diet [25], or polyunsatur-
ated fatty acid supplemented diet [26], or by other drugs
such as lipid-lowering agents [27] or heparin [28], the
beneficial effect was always associated with decreased
proteinuria.
Despite lacking an antiproteinuric effect, calcium
channel blockers cannot be denied to be protective,
though only when started early after renal injury and in
low dosage [14, 15]. Once remnant hypertrophy and
arterial hypertension are established, haemodynami-
cally effective doses of verapamil that control systemic
hypertension will no longer be protective, but worsen
progressive renal failure, a process that is associated
with more rapidly increasing proteinuria.
The mechanisms responsible for progression of renal
failure due to glomerulosclerosis have not been fully
elucidated. Most prominent are the theories of hyper-
filtration [23] and of mesangial overflow with macro-
molecules or toxic lipoproteins [29, 30]. The present
study does not allow us to draw any conclusions regard-
ing other potentially harmful mechanisms such as
simple hyperlipidaemia [27, 31] or uraemic nephro-
calcinosis [20]: plasma lipids at sacrifice showed un-
important differences between groups and overt
nephrocalcinosis was not seen histologically.
Being a potent arteriolar vasodilator, verapamil could
accelerate renal failure by exaggerating hyperfiltration
due to afferent vasodilatation. Such an effect could be
demonstrated by acute experiments in our remnant
kidney model. Intravenous verapamil did in fact
increase renal blood flow and probably also glomerular
capillary pressure, as deduced from an increase in
proximal tubular stop flow pressure despite a marked
decrease in systemic arterial blood pressure [32]. How-
ever, recent observations by Yoshida et al [33] seem to
indicate that increased glomerular capillary pressure
may be less important than the glomerular hypertrophic
response to decreased renal mass. In their hands, triple-
drug antihypertensive treatment with hydralazine,
reserpine, and hydrochlorothiazide was as effective as
enalapril in delaying glomerulosclerosis in strict cor-
relation with retarding glomerular hypertrophy, despite
only minor blunting of the increase in glomerular
capillary pressure by triple-drug therapy compared to
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the marked amelioration of glomerular capillary hyper-
tension by enalapril.
Quite recently, fully antihypertensive calcium channel
blockade by nifedipine started early after 5/6 neph-
rectomy has been shown to inhibit glomerular hyper-
trophy and thereby decrease proteinuria and attenuate
glomerulosclerosis in the absence of any effect on
glomerular capillary hypertension [34]. One could,
therefore, speculate that calcium channel blockers
administered early after renal ablation even in haemo-
dynamically ineffective dosage could delay the morpho-
logical hypertrophic response and thereby protect
against the later development of glomerulosclerosis. In
fact, verapamil has been shown to inhibit compensatory
hypertrophy after uninephrectomy in rats [35] and an
antiproliferative effect of calcium channel blockers has
also been described in a variety of in vitro models [36,
37]. However, when the stage is set for progressive
glomerulosclerosis by undisturbed hypertrophy during
the weeks following renal ablation, no further protec-
tion will be afforded by low-dose calcium antagonists,
whilst high-dose, antihypertensively effective therapy
with such agents might adversely affect glomerular
capillary walls or increase mesangial flooding by macro-
molecules as indicated by the enhanced proteinuria.
In contrast to the human kidney, which shrinks with
chronic progressive renal failure, the failing rat remnant
kidney increases in size [1]. This is correlated with the
degree of proteinuria and appears to result from the
deposition of proteinaceous cast material in dilated
tubular structures [1, 38]. The present study shows
effective antihypertensive treatment with verapamil to
increase the proteinuria as well as the size of the more
rapidly failing remnant kidneys. This is yet another
discrepancy between the rat remnant kidney model and
chronic progressive renal failure in the human. Never-
theless, it is tempting to extrapolate from these findings
in the remnant kidney rat to the patient with chronic
renal disease. Thus, antihypertensive regimens that
decrease proteinuria might be superior to those that do
not affect or even worsen proteinuria, as seems to be the
case for some calcium channel blockers [39].
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